Treatment of pulmonary exacerbations in cystic fibrosis

European Respiratory Review

Volumn 22, Issue 129, 2013, Pages 205-216

  Bhatt, Jayesh M ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B LIPID COMPLEX; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFOXITIN; CHLORHEXIDINE; CIPROFLOXACIN; CLARITHROMYCIN; COLISTIN; CORTICOSTEROID; DORNASE ALFA; FLUCLOXACILLIN; FUSIDIC ACID; ITRACONAZOLE; MANNITOL; MEROPENEM; METICILLIN; OSELTAMIVIR; PREDNISOLONE; PSEUDOMONIC ACID; RIFAMPICIN; SIALIDASE INHIBITOR; SODIUM CHLORIDE; TEICOPLANIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN; VORICONAZOLE;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTIFICIAL VENTILATION; ASPERGILLUS FUMIGATUS; ATYPICAL MYCOBACTERIOSIS; BACTERIUM CULTURE; BRONCHOSCOPY; BURKHOLDERIA CEPACIA; COMORBIDITY; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG INTERMITTENT THERAPY; EARLY DIAGNOSIS; EARLY INTERVENTION; EVIDENCE BASED MEDICINE; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HUMAN; INFLUENZA A; INFLUENZA B; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LUNG FUNCTION TEST; MEDICAL DECISION MAKING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORBIDITY; MORTALITY; MYCOBACTERIUM ABSCESSUS; NUTRITIONAL DEFICIENCY; POLYMERASE CHAIN REACTION; POSITIVE END EXPIRATORY PRESSURE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; REVIEW; RHINOVIRUS; RHINOVIRUS INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SURVIVAL RATE; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; COMORBIDITY; CYSTIC FIBROSIS; DISEASE PROGRESSION; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; HUMANS; PATIENT CARE TEAM; PRACTICE GUIDELINES AS TOPIC; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84883379800     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00006512     Document Type: Review

References (123)

1. Cystic Fibrosis Trust. UK CF Registry Annual data report 2010. www.cysticfibrosis.org.uk/media/108230/ CR_Annual_Data_Report_2010_Dec_11.pdf Date last accessed: April 23, 2012. Date last updated: December 14, 2011.
2. FitzGerald JM. Targeting lung attacks. Thorax 2011; 66: 365-366.
3. Dakin C, Henry RL, Field P, et al. Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol 2001; 31: 436-442.
4. Cunningham JC, Taussig LM. An Introduction to Cystic Fibrosis for Patients and Families. 5th Edn. Cystic Fibrosis Foundation, 2003. www.cff.org/uploadedfiles/treatments/cfcareguidelines/diagnosis/an-introduction-to-cf-for-patientsand-families.pdf Date last accessed April 23, 2012.
5. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749-1756.
6. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23-30.
7. Kraynack NC, Gothard MD, Falletta LM, et al. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers. Pediatr Pulmonol 2011; 46: 870-881.
8. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331: 637-642.
9. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354: 229-240.
10. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, et al. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials 2009; 30: 256-268.
11. Rabin HR, Butler SM, Wohl ME, et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004; 37: 400-406.
12. Regelmann WE, Schechter MS, Wagener JS, et al. Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms. Pediatr Pulmonol 2012 [In press DOI: 10.1002/ppul.22658].
13. Bilton D, Canny G, Conway S, et al. Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros 2011; 10: Suppl. 2, S79-S81.
14. Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009; 180: 802-808.
15. McGrath LT, Mallon P, Dowey L, et al. Oxidative stress during acute respiratory exacerbations in cystic fibrosis. Thorax 1999; 54: 518-523.
16. Downey DG, Brockbank S, Martin SL, et al. The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatr Pulmonol 2007; 42: 729-735.
17. Wieboldt J, Atallah L, Kelly JL, et al. Effect of acute exacerbations on skeletal muscle strength and physical activity in cystic fibrosis. J Cyst Fibros 2012; 11: 209-215.
18. Roderfeld M, Rath T, Schulz R, et al. Serum matrix metalloproteinases in adult CF patients: relation to pulmonary exacerbation. J Cyst Fibros 2009; 8: 338-347.
19. Reid DW, Misso N, Aggarwal S, et al. Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis. Respirology 2007; 12: 63-69.
20. Robroeks CM, Rosias PP, van Vliet D, et al. Biomarkers in exhaled breath condensate indicate presence and severity of cystic fibrosis in children. Pediatr Allergy Immunol 2008; 19: 652-659.
21. Bodini A, D'Orazio C, Peroni D, et al. Biomarkers of neutrophilic inflammation in exhaled air of cystic fibrosis children with bacterial airway infections. Pediatr Pulmonol 2005; 40: 494-499.
22. Bodini A, D'Orazio C, Peroni DG, et al. IL-8 and pH values in exhaled condensate after antibiotics in cystic fibrosis children. Int J Immunopathol Pharmacol 2007; 20: 467-472.
23. Laguna TA, Wagner BD, Starcher B, et al. Urinary desmosine: a biomarker of structural lung injury during CF pulmonary exacerbation. Pediatr Pulmonol 2012; 47: 856-863.
24. Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001; 153: 345-352.
25. Simmonds NJ, Macneill SJ, Cullinan P, et al. Cystic fibrosis and survival to 40 years: a case-control study. Eur Respir J 2010; 36: 1277-1283.
26. Britto MT, Kotagal UR, Hornung RW, et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002; 121: 64-72.
27. Dobbin CJ, Bartlett D, Melehan K, et al. The effect of infective exacerbations on sleep and neurobehavioral function in cystic fibrosis. Am J Respir Crit Care Med 2005; 172: 99-104.
28. Robson M, Abbott J, Webb K, et al. A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients. Thorax 1992; 47: 684-689.
29. Lieu TA, Ray GT, Farmer G, et al. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 1999; 103: e72.
30. Ouyang L, Grosse SD, Amendah DD, et al. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol 2009; 44: 989-996.
31. Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011; 38: 1071-1080.
32. Brody AS, Sucharew H, Campbell JD, et al. Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis. Am J Respir Crit Care Med 2005; 172: 1128-1132.
33. Smith JA, Owen EC, Jones AM, et al. Objective measurement of cough during pulmonary exacerbations in adults with cystic fibrosis. Thorax 2006; 61: 425-429.
34. Schechter MS, McColley SA, Silva S, et al. Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. J Pediatr 2009; 155: 634-639.
35. Goss CH, Newsom SA, Schildcrout JS, et al. Effect of ambient air pollution on pulmonary exacerbations and lung function in cystic fibrosis. Am J Respir Crit Care Med 2004; 169: 816-821.
36. Konstan MW, Morgan WJ, Butler SM, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007; 151: 134-139.
37. Sanders DB, Bittner RC, Rosenfeld M, et al. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011; 46: 393-400.
38. Sanders DB, Bittner RC, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010; 182: 627-632.
39. Stafler P, Davies JC, Balfour-Lynn IM, et al. Bronchoscopy in cystic fibrosis infants diagnosed by newborn screening. Pediatr Pulmonol 2011; 46: 696-700.
40. Pillarisetti N, Williamson E, Linnane B, et al. Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011; 184: 75-81.
41. Mott LS, Park J, Murray CP, et al. Progression of early structural lung disease in young children with cystic fibrosis assessed using CT. Thorax 2012; 67: 509-516.
42. Hoo AF, Thia LP, Nguyen TT, et al. Lung function is abnormal in 3-month-old infants with cystic fibrosis diagnosed by newborn screening. Thorax 2012; 67: 874-881.
43. Wainwright CE, Vidmar S, Armstrong DS, et al. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA 2011; 306: 163-171.
44. Wat D, Gelder C, Hibbitts S, et al. The role of respiratory viruses in cystic fibrosis. J Cyst Fibros 2008; 7: 320-328.
45. Asner S, Waters V, Solomon M, et al. Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis. J Cyst Fibros 2012; 11: 433-439.
46. Ortiz JR, Neuzil KM, Victor JC, et al. Influenza-associated cystic fibrosis pulmonary exacerbations. Chest 2010; 137: 852-860.
47. Viviani L, Assael BM, Kerem E. Impact of the A (H1N1) pandemic influenza (season 2009-2010) on patients with cystic fibrosis. J Cyst Fibrosis 2011; 10: 370-376.
48. Chattoraj SS, Ganesan S, Jones AM, et al. Rhinovirus infection liberates planktonic bacteria from biofilm and increases chemokine responses in cystic fibrosis airway epithelial cells. Thorax 2011; 66: 333-339.
49. Kieninger E, Vareille M, Kopf BS, et al. Lack of an exaggerated inflammatory response on virus infection in cystic fibrosis. Eur Respir J 2012; 39: 297-304.
50. Zemanick ET, Wagner BD, Harris JK, et al. Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures. Pediatr Pulmonol 2010; 45: 569-577.
51. Miall LS, McGinley NT, Brownlee KG, et al. Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis. Arch Dis Child 2001; 84: 160-162.
52. Van Devanter DR, Van Dalfsen JM. How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis? Pediatr Pulmonol 2005; 39: 504-506.
53. Aaron SD, Ramotar K, Ferris W, et al. Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2004; 169: 811-815.
54. Smith AL, Redding G, Doershuk C, et al. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr 1988; 112: 547-554.
55. Regelmann WE, Elliott GR, Warwick WJ, et al. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990; 141: 914-921.
56. Stressmann FA, Rogers GB, Marsh P, et al. Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation? J Cyst Fibros 2011; 10: 357-365.
57. Döring G, Flume P, Heijerman H, et al. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012; 11: 461-479.
58. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
59. Cullen AR, Cannon CL, Mark EJ, et al. Mycobacterium abscessus infection in cystic fibrosis. Colonization or infection? Am J Respir Crit Care Med 2000; 161: 641-645.
60. Esther CR Jr, Esserman DA, Gilligan P, et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibrosis 2010; 9: 117-123.
61. Cystic Fibrosis Trust. Antibiotic treatment for cystic fibrosis. Report of the UK Cystic Fibrosis Trust Antibiotic Working Group. 3rd Edn. London, Cystic Fibrosis Trust, 2009.
62. Thia LP, Balfour Lynn IM. Diagnosing allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Paediatr Respir Rev 2009; 10: 37-42.
63. Shoseyov D, Brownlee KG, Conway SP, et al. Aspergillus bronchitis in cystic fibrosis. Chest 2006; 130: 222-226.
64. Chotirmall SH, O'Donoghue E, Bennett K, et al. Sputum Candida albicans presages FEV1 decline and hospitaltreated exacerbations in cystic fibrosis. Chest 2010; 138: 1186-1195.
65. Smyth A, Elborn JS. Exacerbations in cystic fibrosis: 3-Management. Thorax 2008; 63: 180-184.
66. Szaff M, Høiby N. Antibiotic treatment of Staphylococcus aureus infection in cystic brosis. Acta Paediatr Scand 1982; 71: 821-826.
67. Pressler T, Szaff M, Høiby N. Antibiotic treatment of Haemophilus inuenzae and Haemophilus parainuenzae infections in patients with cystic fibrosis. Acta Paediatr Scand 1984; 73: 541-547.
68. Rayner RJ, Hiller EJ, Ispahani P, et al. Haemophilus infection in cystic brosis. Arch Dis Child 1990; 65: 255-258.
69. Briggs EC, Nguyen T, Wall MA, et al. Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience. Clin Respir J 2012; 6: 56-64.
70. Touw DJ, Brimicombe RW, Hodson ME, et al. Inhalation of antibiotics in cystic fibrosis. Eur Respir J 1995; 8: 1594-1604.
71. Johnson C, Butler SM, Konstan MW, et al. Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest 2003; 123: 20-27.
72. Gilchrist FJ, Lenney W. A review of the home intravenous antibiotic service available to children with cystic fibrosis. Arch Dis Child 2009; 94: 647.
73. Bosworth DG, Nielson DW. Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis. Pediatr Pulmonol 1997; 24: 42-47.
74. Thornton J, Elliott R, Tully MP, et al. Long term clinical outcome and hospital intravenous antibiotic treatment in adults with cystic fibrosis. Thorax 2004; 59: 242-246.
75. Termoz A, Touzet S, Bourdy S, et al. Effectiveness of home treatment for patients with cystic fibrosis: the intravenous administration of antibiotics to treat respiratory infections. Pediatr Pulmonol 2008; 43: 908-915.
76. Nazer D, Abdulhamid I, Thomas R, et al. Home versus hospital intravenous antibiotic therapy for acute pulmonary exacerbations in children with cystic fibrosis. Pediatr Pulmonol 2006; 41: 744-749.
77. Collaco JM, Green DM, Cutting GR, et al. Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am J Respir Crit Care Med 2010; 182: 1137-1143.
78. Aaron SD, Ferris W, Ramotar K, et al. Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis. J Clin Microbiol 2002; 40: 4172-4179.
79. Hurley MN, Ariff AH, Bertenshaw C, et al. Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. J Cyst Fibros 2012; 11: 288-292.
80. Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2012; 2: CD002009.
81. Brown SM, Balfour-Lynn IM. Duration of intravenous antibiotic treatment for respiratory exacerbations in children with cystic fibrosis. Arch Dis Child 2010; 95: 568.
82. Plummer A, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev 2011; 1: CD006682.
83. Parkins MD, Rendall JC, Elborn JS. Incidence and risk factors for pulmonary exacerbation treatment failures in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa. Chest 2012; 141: 485-493.
84. Jagannath VA, Asokan GV, Fedorowicz Z, et al. Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. Cochrane Database Syst Rev 2010; 3: CD008139.
85. Fauroux B. Why, when and how to propose noninvasive ventilation in cystic fibrosis? Minerva Anestesiol 2011; 77: 1108-1114.
86. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354: 241-250.
87. Daviskas E, Anderson SD, Jaques A, et al. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. Chest 2010; 137: 861-868.
88. Reeves EP, Williamson M, O'Neill SJ, et al. Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med 2011; 183: 1517-1523.
89. Amin R, Subbarao P, Jabar A, et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax 2010; 65: 379-383.
90. Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2009; 2: CD001506.
91. Wilmott RW, Amin RS, Colin AA, et al. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. Am J Respir Crit Care Med 1996; 153: 1914-1917.
92. Slattery DM, Waltz DA, Denham B, et al. Bronchoscopically administered recombinant human DNase for lobar atelectasis in cystic fibrosis. Pediatr Pulmonol 2001; 31: 383-388.
93. Moran A, Hardin D, Rodman D, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract 1999; 45: 61-73.
94. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37: Suppl. 3, S225-S264.
95. Barone JA, Moskovitz BL, Guarnieri J, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-bcyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 1862-1865.
96. Bae SK, Park SJ, Shim EJ, et al. Increased oral bioavailability of itraconazole and its active metabolite, 7-hydroxyitraconazole, when coadministered with a vitamin C beverage in healthy participants. J Clin Pharmacol 2011; 51: 444-451.
97. Bentley S, Gupta A, Balfour-Lynn IM. Subtherapeutic itraconazole and voriconazole levels in children with cystic fibrosis. J Cyst Fibros 2013; 12: 418-419.
98. Hilliard T, Edwards S, Buchdahl R, et al. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibros 2005; 4: 215-220.
99. Glackin L, Leen G, Elnazir B, et al. Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. Ir Med J 2009; 102: 29.
100. Rondeau S, Couderc L, Dominique S, et al. High frequency of voriconazole-related phototoxicity in cystic fibrosis patients. Eur Respir J 2012; 39: 782-784.
101. Epaulard O, Leccia MT, Blanche S, et al. Phototoxicity and photocarcinogenesis associated with voriconazole. Med Mal Infect 2011; 41: 639-645.
102. Laoudi Y, Paolini JB, Grimfed A, et al. Nebulised corticosteroid and amphotericin B: an alternative treatment for ABPA? Eur Respir J 2008; 31: 908-909.
103. Godet C, Meurice JC, Roblot F, et al. Efficacy of nebulised liposomal amphotericin B in the attack and maintenance treatment of ABPA. Eur Respir J 2012; 39: 1261-1263.
104. Smyth A, Walters S. Prophylactic antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003; 3: CD001912.
105. Tramper-Stranders GA, Wolfs TF, van Haren Noman S, et al. Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Thorax 2010; 65: 915-920.
106. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2009; 4: CD004197.
107. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011; 165: 847-856.
108. Mayer-Hamblett N, Kronmal RA, Gibson RL, et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol 2012; 47: 125-134.
109. Saiman L. Infection prevention and control in cystic fibrosis. Curr Opin Infect Dis 2011; 24: 390-395.
110. Dharmaraj P, Smyth RL. Vaccines for preventing influenza in people with cystic fibrosis. Cochrane Database Syst Rev 2009; 4: CD001753.
111. Sermet-Gaudelus I, Mayell SJ, Southern KW, et al. Guidelines on the early management of infants diagnosed with cystic fibrosis following newborn screening. J Cyst Fibros 2010; 9: 323-329.
112. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002; 121: 55-63.
113. Quan JM, Tiddens HA, Sy JP, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001; 139: 813-820.
114. Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst Rev 2007; 4: CD001505.
115. Southern KW, Barker PM, Solis-Moya A, et al. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2011; 12: CD002203.
116. Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010; 303: 1707-1715.
117. Rosenfeld M, Ratjen F, Brumback L, et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA 2012; 307: 2269-2277.
118. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365: 1663-1672.
119. Schnabel D, Grasemann C, Staab D, et al. A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics 2007; 119: e1230-e1238.
120. Hurley MN, Forrester DL, Smyth AR. Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. Cochrane Database Syst Rev 2010; 10: CD008037.
121. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957-969.
122. Bell SC, Robinson PJ. Exacerbations in cystic fibrosis: 2. prevention. Thorax 2007; 62: 723-732.
123. Moskowitz SM, Silva SJ, Mayer-Hamblett N, et al. Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr Pulmonol 2008; 43: 874-881.